Delcath Systems (DCTH) Stock Analysis & AI Equity Report

Medical - Specialties USD Explore free reports

Delcath Systems (DCTH) overview

Delcath Systems (DCTH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 85.2m and operating profit of USD 0.7m; the year-end share price was 10.10 USD and market capitalisation was USD 350m. Delcath Systems is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Delcath Systems's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 111mFY 2025
Share price10.10 USDFY 2025 year end
RevenueUSD 85.2mFY 2025
Operating profitUSD 0.7mFY 2025
Net earningsUSD 2.7mFY 2025
Market capitalisationUSD 350mFY 2025 year end

About Delcath Systems

Delcath Systems focuses on interventional oncology treatments for cancers originating in or spreading to the liver. Its HEPZATO KIT combines melphalan for injection with a hepatic delivery system and is approved in the United States for certain adults with metastatic uveal melanoma. In Europe, its CHEMOSAT system is a standalone hepatic delivery medical device used at medical centers to treat liver cancers.

Generate the Delcath Systems report

Delcath Systems is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Delcath Systems and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Delcath Systems

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.